Johnson & Johnson's oncology portfolio gains momentum with new clinical data for prostate cancer drug Erleada and a broader FDA label for multiple myeloma therapy Darzalex Faspro, reinforcing its competitive stance in key cancer markets.
With its patented, FDA-recognized compound Niagen®, Niagen Bioscience (NAGE) has carved out a unique and defensible position at the intersection of nutraceuticals and pharmaceuticals. As the cellular health market expands, the company's dual-channel strategy and deep scientific validation present a compelling growth narrative for investors.
As the wearables market surges, Biolinq CEO Richard Yang positions smart patches as the next evolution, capable of tracking deep biochemical data where watches track surface metrics, with his company's FDA-cleared glucose sensor leading the charge.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
Millions of sole traders and landlords face a fundamental change in how late tax submissions are penalized, as HMRC prepares to replace automatic fines with a points-based regime starting in 2026.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Acadia Pharmaceuticals faces a setback as European regulators issue a negative opinion on its Rett syndrome therapy trofinetide, casting uncertainty over its EU approval pathway and highlighting the challenges of bringing rare disease treatments to new markets.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
A nationwide class action lawsuit alleges Costco's Kirkland Signature Rotisserie Chicken is misleadingly marketed as having 'No Preservatives,' spotlighting growing scrutiny over clean-label claims in the grocery sector and potential risks to the retailer's reputation.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.
Cronos Group's stock has rallied on renewed optimism for U.S. cannabis reform. We examine the regulatory shift, strategic positioning, and long-term potential driving investor sentiment.
ResMed Inc., the sleep therapy giant, faces a pivotal moment. While benefiting from a competitor's recall and a growing market funnel, emerging oral treatments and shifting dynamics pose fresh challenges to its long-held CPAP business model.
Insulet Corporation (NASDAQ: PODD), the maker of the tubeless Omnipod insulin delivery system, is drawing investor attention with a potent mix of surging cash flow, market expansion, and a recurring revenue model. As the company capitalizes on recent regulatory wins and international growth, we examine the bull case and the risks ahead.
Despite recent stock pressure from its CRM platform migration, Veeva Systems' deep integration in life sciences workflows, robust financials, and expanding AI product suite present a compelling long-term investment case, analysts argue.
The Hong Kong Monetary Authority (HKMA) is poised to grant its inaugural stablecoin issuer licenses next month, a key step in the city's comprehensive push to establish a regulated digital asset ecosystem. The move follows a rigorous application process and signals a new era of oversight for the burgeoning sector.
The Internal Revenue Service's free online tracker is now active for taxpayers who have filed their 2025 returns, providing daily updates on refund status and estimated deposit dates for 2026.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
